T1	p 109 117	Autism .
T2	p 150 158	disorder
T3	p 172 196	autism spectrum disorder
T4	p 612 680	Age-matched boys with ADHD ( 15 ) , ASD ( 18 ) , and controls ( 21 )
T5	p 947 955	patients
T6	p 965 994	drug effects . Patients under
T7	p 1117 1147	ASD boys underactivated medial
T8	i 24 34	Fluoxetine
T9	i 337 356	reuptake inhibitors
T10	i 700 746	functional magnetic resonance imaging ( fMRI )
T11	i 824 853	dose of Fluoxetine or placebo
T12	i 874 892	placebo-controlled
T13	i 1077 1081	fMRI
T14	i 1107 1114	placebo
T15	i 1281 1291	Fluoxetine
T16	i 1421 1428	placebo
T17	i 1491 1501	Fluoxetine
T18	o 38 73	Medial Prefrontal Cortex Activation
T19	o 81 96	Reward Reversal
T20	o 109 165	Autism . Attention deficit hyperactivity disorder ( ADHD
T21	o 211 239	brain function abnormalities
T22	o 247 268	cognitive flexibility
T23	o 390 401	flexibility
T24	o 406 422	improve behavior
T25	o 503 521	brain dysfunctions
T26	o 1067 1074	effects
T27	o 1121 1176	boys underactivated medial prefrontal cortex ( mPFC ) ,
T28	o 1252 1330	precuneus activation . Under Fluoxetine , mPFC activation was up-regulated and
T29	o 1469 1480	performance
T30	o 1535 1550	mPFC activation
T31	o 1562 1566	ADHD
T32	o 1574 1591	reversal learning
T33	o 1638 1651	abnormalities